Abstract
Technology: Somatropin. Indication: Growth disorder in children born small
2
Fernandes Nascimento MH, Fernandes RM, Barbosa AM. Eficácia e segurança de somatropina para o tratamento de crianças
nascidas pequenas para a idade gestacional: revisão rápida de evidências. Rev Cient Esc Estadual Saúde Pública Goiás
“Cândido Santiago”. 2022;8(e80021):1-13.
for gestational age (SGA). Question: Is somatropin effective, safe and cost effective for
promoting height gain in children born SGA? Methods: A bibliographic search was done in
PUBMED database, following predefined search strategies. The methodological quality of
systematic reviews was evaluated using the AMSTAR-2 tool (A MeaSurement Tool to Assess
systematic Reviews version 2). Results: Only a systematic review met the inclusion criteria and
was selected. Conclusion: Evidence of moderate certainty indicates that somatropin is effective
and safe for the treatment of children born SGA, because the treatment improve the growth and
there are no reports of serious adverse events in the scientific literature.